

In the claims:

Please cancel claims 4, 9 and 17 without prejudice.

3. (Amended) A method of inhibiting the adhesion of a first cell bearing an E-selectin [a first selectin] molecule to a second cell bearing an L-selectin [a second selectin] molecule [, said selectin molecules being different,] comprising:

contacting said cells with the antibodies or antigen binding fragments of claim 1 under ~~✓~~ conditions wherein the antibodies bind to the cells in an amount sufficient to prevent the first cell from binding to the second cell.

10. (Twice Amended) A method of treating a mammal to [prevent or] inhibit tissue damage occurring at an inflammatory site in any part of the body of a mammal experiencing a leukocyte-mediated inflammatory condition, said method comprising:

23 administering *in vivo* a monoclonal antibody, having specificity for a common antigenic determinant on E-selectin and L-selectin in an amount sufficient to bind specifically to L-selectin and E-selectin molecules expressed on the surface of leukocytes and endothelial cells, respectively to inhibit the adhesion of said cells.

24. (Amended) A monoclonal antibody which specifically binds a common antigenic determinant on E-selectin and L-selectin produced by a process comprising:

- 24 (a) immunizing a mammal with an immunogen composed of cells stably expressing E-selectin, cells stably expressing L-selectin or a combination of cells stably expressing E-selectin and cells stably expressing L-selectin;
- (b) fusing lymphocytes from the immunized mammal with myeloma cells;

- (c) selecting hybrid cells that secrete antibodies that [recognize] specifically bind a common antigenic determinant on L-selectin and E-selectin; and
(d) isolating the antibodies.

25. (Amended) A process for producing monoclonal antibodies which specifically bind to a common antigenic determinant on E-selectin and L-selectin comprising:

- (a) immunizing a mammal with an immunogen composed of cells stably expressing E-selectin, cells stably expressing L-selectin or a combination of cells stably expressing E-selectin and cells stably expressing L-selectin;
(b) fusing lymphocytes from the immunized mammal with myeloma cells;
(c) selecting hybrid cells that secret antibodies that specifically bind a common antigenic determinant on L-selectin and E-selectin; and
(d) isolating the antibodies.

26. (Amended) A method of [preventing or] inhibiting an inflammatory response at a site of ischemia-reperfusion injury in a mammal, said method comprising:

administration of an effective amount of a monoclonal antibody or antigen binding fragment thereof, said antibody or antigen binding fragment, having specificity for a common antigenic determinant on E-selectin and L-selectin and specifically binds to the common antigenic determinant of L-selectin and E-selectin, said amount [prevents or] inhibits the inflammatory response at the site of ischemia-reperfusion injury.

37
28. (Amended) The method according to claim 26 wherein the [inflammatory response] ischemic injury is caused by a myocardial infarction, shock, stroke, organ transplantation, crush injury, limb replantation, frostbite or lung ischemia/reperfusion injury.

30. (Amended) A method to [prevent or] inhibit leukocyte rolling on an endothelial cell layer comprising:

treatment of the leukocytes or the endothelial cell layer with an amount of the monoclonal antibody or antigen binding fragment according to claim 1, said amount is effective to [prevent or] inhibit leukocyte rolling.

31. (Amended) The method according to claim 30 wherein the endothelial cell layer is [in] an endothelium lining a lymphatic vessel, artery, vein or postcapillary venules.

32. (Amended) A method to [prevent or] inhibit lymphocyte homing to peripheral tissue of a mammal comprising:

administration of an effective amount of the monoclonal antibody or antigen binding fragment according to claim 1, said amount [prevents or] inhibits the homing of lymphocytes from the blood to the peripheral tissue.

Please add the following new claims:

35. (New) The method according to claim 8 wherein the E-selectin and L-selectin bearing cells are at a site of inflammation in a mammal.

36. (New) The pharmaceutical composition according to claim 18 further comprising an anti-inflammatory agent selected from the group consisting of: catecholamines, resorcinols, salingenins, ephedrine, glucocorticoids, eromolyn sodium, and anticholinergics.

- 27
37. (New) The monoclonal antibody according to claim 24 wherein the immunogen is a human E-selectin cDNA transfected cell.
38. (New) The method according to claim 25 wherein immunogen is a human E-selectin cDNA transfected cell.
39. (New) The method according to claim 28, wherein said amount is effective to inhibit loss of lung function.
-